Low dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy

Trial Profile

Low dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy

Completed
Phase of Trial: Phase III

Latest Information Update: 16 May 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Diabetic retinopathy; Postoperative haemorrhage
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 18 Mar 2013 Planned End Date 30 Sep 2013 added as reported by University Hospital Medical Information Network - Japan.
    • 18 Mar 2013 Planned number of patients changed from 120 to 60 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top